Cargando…
Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs)....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323888/ https://www.ncbi.nlm.nih.gov/pubmed/35891326 http://dx.doi.org/10.3390/vaccines10071163 |
_version_ | 1784756668644458496 |
---|---|
author | Grikscheit, Katharina Rabenau, Holger F. Ghodratian, Zahra Widera, Marek Wilhelm, Alexander Toptan Grabmair, Tuna Hoehl, Sebastian Layer, Emily Helfritz, Fabian Ciesek, Sandra |
author_facet | Grikscheit, Katharina Rabenau, Holger F. Ghodratian, Zahra Widera, Marek Wilhelm, Alexander Toptan Grabmair, Tuna Hoehl, Sebastian Layer, Emily Helfritz, Fabian Ciesek, Sandra |
author_sort | Grikscheit, Katharina |
collection | PubMed |
description | The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from subjects before and two and seven weeks after the second booster or after Omicron infection were examined for the level of Spike receptor-binding-domain (RBD)-specific antibodies. Furthermore, neutralizing antibodies (nABs) were characterized in in vitro neutralization assays comparing the variants of concern Alpha, Beta, Delta, and Omicron BA.1 and BA.2 against the ancestral strain B.1. Here, the second booster resulted in an increase in anti-RBD-IgG-antibodies, remaining nearly constant over time, accompanied by an increase in nABs against B.1 and the VOCs Alpha, Beta, Delta, and Omicron BA.1 and BA.2. However, compared to B.1, the neutralizing capacity against the Omicron subvariants remained low and was limited after the second booster vaccination. This indicates that antibody-mediated protection against infection with this VOC is unlikely, as evidenced by the fact that three individuals of our study cohort became infected with Omicron BA.1 after the second booster. T cell activation was measured by interferon-gamma release assays in a subgroup of subjects and was increased in all subjects tested after the second booster vaccination, correlating with the amount of Spike-specific antibodies. In subjects with Omicron BA.1 breakthrough infection, a significant increase in nABs to all VOCs studied was observed independently of booster vaccinations. Taken together, our data indicate that a second booster or Omicron BA.1 infection mediate a substantial increase in anti-Spike IgG antibodies; however, infection with Omicron BA.1 induced a stronger increase in neutralizing antibodies against the different VOCs |
format | Online Article Text |
id | pubmed-9323888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93238882022-07-27 Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination Grikscheit, Katharina Rabenau, Holger F. Ghodratian, Zahra Widera, Marek Wilhelm, Alexander Toptan Grabmair, Tuna Hoehl, Sebastian Layer, Emily Helfritz, Fabian Ciesek, Sandra Vaccines (Basel) Article The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from subjects before and two and seven weeks after the second booster or after Omicron infection were examined for the level of Spike receptor-binding-domain (RBD)-specific antibodies. Furthermore, neutralizing antibodies (nABs) were characterized in in vitro neutralization assays comparing the variants of concern Alpha, Beta, Delta, and Omicron BA.1 and BA.2 against the ancestral strain B.1. Here, the second booster resulted in an increase in anti-RBD-IgG-antibodies, remaining nearly constant over time, accompanied by an increase in nABs against B.1 and the VOCs Alpha, Beta, Delta, and Omicron BA.1 and BA.2. However, compared to B.1, the neutralizing capacity against the Omicron subvariants remained low and was limited after the second booster vaccination. This indicates that antibody-mediated protection against infection with this VOC is unlikely, as evidenced by the fact that three individuals of our study cohort became infected with Omicron BA.1 after the second booster. T cell activation was measured by interferon-gamma release assays in a subgroup of subjects and was increased in all subjects tested after the second booster vaccination, correlating with the amount of Spike-specific antibodies. In subjects with Omicron BA.1 breakthrough infection, a significant increase in nABs to all VOCs studied was observed independently of booster vaccinations. Taken together, our data indicate that a second booster or Omicron BA.1 infection mediate a substantial increase in anti-Spike IgG antibodies; however, infection with Omicron BA.1 induced a stronger increase in neutralizing antibodies against the different VOCs MDPI 2022-07-21 /pmc/articles/PMC9323888/ /pubmed/35891326 http://dx.doi.org/10.3390/vaccines10071163 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grikscheit, Katharina Rabenau, Holger F. Ghodratian, Zahra Widera, Marek Wilhelm, Alexander Toptan Grabmair, Tuna Hoehl, Sebastian Layer, Emily Helfritz, Fabian Ciesek, Sandra Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title | Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title_full | Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title_fullStr | Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title_full_unstemmed | Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title_short | Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination |
title_sort | characterization of the antibody and interferon-gamma release response after a second covid-19 booster vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323888/ https://www.ncbi.nlm.nih.gov/pubmed/35891326 http://dx.doi.org/10.3390/vaccines10071163 |
work_keys_str_mv | AT grikscheitkatharina characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT rabenauholgerf characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT ghodratianzahra characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT wideramarek characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT wilhelmalexander characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT toptangrabmairtuna characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT hoehlsebastian characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT layeremily characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT helfritzfabian characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination AT cieseksandra characterizationoftheantibodyandinterferongammareleaseresponseafterasecondcovid19boostervaccination |